Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. has demonstrated a positive outlook driven by the successful expansion of its Cortrophin sales force, which has significantly contributed to Cortrophin's sales performance. The company's effective data-driven strategy has enhanced its ability to respond to payer inquiries, leading to improved approval rates for prescriptions, further supporting revenue growth. Additionally, increased estimates for Cortrophin revenue suggest positive momentum and potential for multiple expansion, strengthening ANI's financial prospects.

Bears say

ANI Pharmaceuticals Inc. faces significant challenges, including a debt load exceeding $600 million and various operational risks such as pricing fluctuations, reimbursement issues, and manufacturing concerns. The company’s product categories are susceptible to competitive threats which could adversely affect revenue generation. Additionally, historical reputational issues linked to the ACTH market could further hinder investor confidence and commercial execution.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.